Hainaut Pierre, Wiman Klas G
International Agency for Research on Cancer, Lyon, France.
Lancet Oncol. 2009 Sep;10(9):913-9. doi: 10.1016/S1470-2045(09)70198-6.
Among the 278,092 publications indexed into PubMed in 1979, a handful of articles stand out as the foundation of one of the most profound forays into the molecular basis of carcinogenesis: the discovery of the p53 tumour-suppressor protein. In the 30 years since then, understanding of p53 has progressed from obscure oncogene to key tumour-suppressor gene with clinical potential. Yet, p53 research has not followed a straight course. In this Historical Review, we describe how the 1979 discovery has shaped our view of the molecular basis of cancer, and identify some crucial steps ahead to transfer the wealth of knowledge accumulated on p53 into applications to cancer prevention and treatment.
在1979年被收录进PubMed的278,092篇出版物中，有几篇文章脱颖而出，成为了对致癌作用分子基础最深入探索之一的基石：p53肿瘤抑制蛋白的发现。从那时起的30年里，对p53的认识已从模糊的癌基因发展成为具有临床潜力的关键肿瘤抑制基因。然而，p53的研究并非一帆风顺。在这篇历史综述中，我们描述了1979年的这一发现如何塑造了我们对癌症分子基础的看法，并确定了一些关键的后续步骤，以便将积累的关于p53的丰富知识转化为癌症预防和治疗的应用。
